Physician profile
Brian Wallin
NPI 1336401728
$1,158.22
in general payments reported to CMS, 2019-2025
17 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $552 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $134.33 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $118.28 | 2024-2025 | Veozah |
| Pfizer INC. | $108.38 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $103.75 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.10 | 2025 | Caplyta |
| Lilly USA, LLC | $88.93 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $86.51 | 2024-2025 | |
| Inspire Medical Systems, INC. | $76.90 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $71.17 | 2024-2025 | Spravato |
| Exact Sciences Corporation | $53.43 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.39 | 2024 | Ofev |
| Medtronic, INC. | $43.58 | 2024-2025 | Interstim |
| Amgen INC. | $34.99 | 2024-2025 | Evenity, Prolia |
| Boston Scientific Corporation | $23.86 | 2025 | General - Pain Management |
| Bausch Health US, LLC | $23.77 | 2025 | Wellbutrin, Aplenzin |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.50 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.35 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wallin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.